Cambodia

Population 2017 16 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>3.1 (2.4–3.5)</td>
<td>19 (13–27)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.41 (0.27–0.57)</td>
<td>2.6 (1.7–3.6)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>52 (36–72)</td>
<td>328 (224–447)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.3 (0.89–1.8)</td>
<td>8.2 (5.6–11)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>1.2 (0.52–2.1)</td>
<td>7.2 (3.2–13)</td>
</tr>
</tbody>
</table>

Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>3.1 (1.4–4.8)</td>
<td>3.4 (1.6–5.3)</td>
<td>6.5 (4–9.1)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>19 (8.6–29)</td>
<td>27 (12–41)</td>
<td>46 (28–63)</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- Total cases notified: 34,467
- Total new and relapse: 34,238
- % tested with rapid diagnostics at time of diagnosis: 87%
- % with known HIV status: 66%
- % bacteriologically confirmed among pulmonary: 54%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 66% (48–96)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2017: 0.07 (0.04–0.1)

Drug-resistant TB care, 2017

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 560 (290–840)
- % notified tested for rifampicin resistance: 33%
- % notified for rifampicin resistance: 1.8% (0.9–3) among notified TB cases
- % bacteriologically confirmed among pulmonary: 11% (3.2–22)
- MDR/RR-TB cases tested for resistance to second-line drugs: 100

Laboratory-confirmed cases

- MDR/RR-TB: 136, XDR-TB: 1

Patients started on treatment ****

- MDR/RR-TB: 143, XDR-TB: 1

Treatment success rate and cohort size

- New and relapse cases registered in 2016: 94% (32,478)
- Previously treated cases, excluding relapse, registered in 2016: 92% (36)
- HIV-positive TB cases registered in 2016: 71% (75)

TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 21%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 44% (40–48)

TB financing, 2018

- National TB budget (US$ millions): 37

- Funding source: 12% domestic, 24% international, 64% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-07-23

Data: www.who.int/tb/data